Dysregulation of the hypothalamic–pituitary–adrenal axis can facilitate tumor progression through the upregulation of signaling molecules such as fibroblast growth factor 2 and activation of epithelial–mesenchymal transition pathway (64). Here, FGF2 is linked to neoplasm.